What drives XtalPi’s revenue growth?

Revenue growth comes from AI-driven drug discovery services and early licensing deals. 2024 revenue rose 52.75% year-on-year, driven by platform adoption and expanded service contracts with pharma partners.

Is 2228.HK a bargain at current PE?

The quoted PE of 9.70 looks low versus healthcare peers, but abnormal cash-flow and high R&D spending mean investors should weigh margin recovery and licensing scale before treating it as a value buy.

What are the main near-term catalysts to watch?

Watch results from pilot licensing deals, announcements of pharma partnerships, quarterly revenue trends, and the earnings date on 2026-03-27. Positive license conversions would improve valuation momentum.

How should traders manage risk on 2228.HK?

Use technical levels: support near HKD 9.00 and resistance near HKD 10.26; size positions given long receivable days and cash-flow weakness. Keep stop-losses and watch volume for conviction.

HK Stocks

XtalPi (2228.HK) HKD 9.99 pre-market 03 Jan 2026: AI drug discovery trade-off

ByHuzaifa Zahoor January 3, 2026January 3, 2026

Opening at HKD 9.99 pre-market on 03 Jan 2026, 2228.HK (XtalPi Holdings Ltd) is trading near its 50-day average after a 5.60% intraday move. Investors focused on AI stocks will watch XtalPi’s AI-driven platforms — XMolGen and XtalFold — as revenue growth accelerates but margins remain pressured. The stock trades at a quoted PE of 9.70 and market cap HKD 42.99B, while shorter-term momentum indicators are neutral. This note lays out valuation, technical signals, catalysts and model forecasts for trading in Hong Kong (HKSE)